Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Cancer|April 2, 2025
BRAF in non-small cell lung cancer: From molecular mechanisms to clinical practiceClaudia Parisi, David Planchard
Drugs|January 31, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Pamela Abdayem, Claudia Parisi, David Planchard
Cancer|June 1, 2026
Mapping the antibody-drug-conjugates landscape in non-small cell lung cancer: Where are we and where are we going?Claudia Parisi, Fabrice Barlesi, David Planchard
Giornale Italiano Di Cardiologia (2006)|November 7, 2017
[Sinus bradycardia and syncope: what pathophysiological mechanism and what management of the patient?]Paolo Alboni, Nicola Stucci, Claudia Parisi
Transgenic Research|August 18, 2012
Analysing patent landscapes in plant biotechnology and new plant breeding techniquesClaudia Parisi, Emilio Rodríguez-Cerezo, Harry Thangaraj
Cancer Treatment Reviews|May 25, 2023
TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)Claudia Parisi, Linda Mahjoubi, Anas Gazzah, et al.
European Journal of Cancer (Oxford, England : 1990)|September 9, 2021
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?Alessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Critical Reviews in Oncology/Hematology|March 23, 2021
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategyAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
JTO Clinical and Research Reports|September 30, 2021
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
Evolution of cystic airspaces lung lesions on immune checkpoint inhibition in non-small cell lung cancerClaudia Parisi, Giuseppe Lamberti, Maurizio Zompatori, et al.
Pageof 6